Clinical trial · Observational
The Predictive Value of Serum Histone Succinylation in Malignant Solid Tumors
Serum Histone Succinylation: A Predictive Biomarker for Malignant Solid Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In recent years, advances in protein post-translational modification (PTM) research have revealed histone succinylation as a novel epigenetic modification mechanism critically involved in tumor initiation, progression, and prognosis. Succinylation alters protein physicochemical properties and functions, thereby modulating cellular metabolism, proliferation, and apoptosis. Aberrant histone succinylation in tumor cells demonstrates significant correlations with tumor type, staging, and clinical outcomes, offering new avenues for early cancer diagnosis. This project utilizes blood serum samples to quantify histone succinylation levels through modification-specific antibody-based detection. Integrated with clinical data, this approach enables early, rapid, and accurate pan-cancer diagnosis, achieving tumor screening via a single-tube blood test. It represents a paradigm shift in precision oncology from "gene-driven" to "epigenetic-metabolic-driven" early detection.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Tumors | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- 500 patients with malignant solid tumors
- description
- Aged ≥18 years, regardless of sex； Histologically or cytologically confirmed malignant solid tumors requiring subsequent anticancer therapy
Primary outcomes (1)
- measure
- Evaluate the positive rate of serum histone succinylation in patients with malignant solid tumors
- timeFrame
- 2025.08.01-2026.12.31
- description
- Evaluate the positive rate of serum histone succinylation in malignant solid tumor patients versus healthy individuals through Western blot analysis, quantify the percentage difference between the two groups, and thereby validate its potential for early cancer screening
Secondary outcomes (1)
- measure
- Define the relationship between histone succinylation modifications in serum and different tumor types as well as tumor staging
- timeFrame
- 2025.08.01-2026.12.31
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Case Group: * Aged ≥18 years, regardless of sex； * Histologically or cytologically confirmed malignant solid tumors requiring subsequent anticancer therapy； Control Group: * Aged ≥18 years, regardless of sex； * Non-cancer participants enrolled through health screenings； Exclusion Criteria: * Pregnant individuals； * Individuals with serious mental disorders or communication barriers； * Other conditions deemed by investigators to contraindicate study participation；
References
Publications (0)
Data not yet available